In the dynamic and fragmented Generic and Specialty Drug industry, besieged by intense competition and rapid change of technological innovations, the ability to anticipate new product introductions and marketing strategies is particularly important...and can spell the difference between success and failure.
This collection of strategic assessments of leading Generic and Specialty Drug companies provides significant competitor information, analysis and insight critical to the development and implementation of effective business, marketing and R&D programs. The assessments include latest organizational and management developments, acquisitions and divestitures, marketing tactics, financial results, strengths and weaknesses, and strategic directions.
These reports will complement your internal competitor information gathering efforts with objective strategic analysis, data interpretation and insight.
The reports will also assist current competitors and potential market entrants in evaluating prospective acquisitions and joint venture candidates.
This collection of strategic assessments of leading Generic and Specialty Drug companies provides significant competitor information, analysis and insight critical to the development and implementation of effective business, marketing and R&D programs. The assessments include latest organizational and management developments, acquisitions and divestitures, marketing tactics, financial results, strengths and weaknesses, and strategic directions.
- Aurora Cannabis
- Canopy Growth
- Cronos Group
- Curaleaf
- Dr. Reddy's Laboratories
- Green Thumb
- Merck
- MomentaPharma
- Mylan
- Perrigo
- Teva Pharma
- Tilray
- oetis
These reports will complement your internal competitor information gathering efforts with objective strategic analysis, data interpretation and insight.
The reports will also assist current competitors and potential market entrants in evaluating prospective acquisitions and joint venture candidates.
